Pierre-Yves Berclaz

Pierre-Yves Berclaz

Executive Vice President and Chief Medical Officer

Pierre-Yves was appointed Chief Medical Officer in January 2023 and has responsibility for Medical Affairs, Pharmacovigilance, Quality Assurance, Value & Access and Bioethics activities.

Pierre-Yves brings extensive medical and scientific expertise to Ferring, having previously held the position of Senior Vice President, Head of Global Medical Affairs for Neurology and Immunology at Merck KGaA/EMD Serono, based in Boston, USA.

Prior to this, Pierre-Yves spent over 14 years at Eli Lilly, holding leadership roles in Medical Affairs, Global Clinical Development, Clinical Pharmacology and Discovery Research in multiple therapeutic areas, including immunology, neuroscience, diabetology and oncology. Pierre-Yves also spent seven years as Chief Medical Officer for Eli Lilly Japan, where he led the clinical and medical efforts in the successful launches of numerous new molecular entities (NMEs) and line extensions. His focus on safeguarding patients’ best interests has been a constant driver in his career.

This page is not intended for patients or for members of the general public. It is only intended to be used by healthcare professionals.

OK

Cette page n'est pas destinée aux patients ou au grand public. Il est uniquement destiné à être utilisé par des professionnels de santé.

OK

Ik bevestig dat ik een professionele zorgverlener ben of een zakelijke relatie heb met Ferring Pharmaceuticals

OK

Ez az oldal nem betegeknek, vagy nagyközönségnek szól. Az oldalt kizárólag egészségügyi szakemberek használhatják.

OK

Ta strona nie jest przeznaczona dla pacjentów ani dla ogółu odwiedzających. Ta strona stworzona jest dla pracowników sektora ochrony zdrowia.

OK

Эта страница не предназначена для пациентов или для широкой публики. Она предназначена только для медицинских работников.

OK